Basic Information
| LncRNA/CircRNA Name | HOXA-AS2 |
| Synonyms | HOXA-AS2, HOXA3as |
| Region | GRCh38_7:27107777-27134302 |
| Ensemble | ENSG00000253552 |
| Refseq | NR_122069 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | pancreatic cancer |
| ICD-0-3 | C25 |
| Methods | qPCR, RIP |
| Sample | pancreatic cancer tissues, cell lines (AsPC-1,BxPC-3, and PANC-1) |
| Expression Pattern | up-regulated |
| Function Description | HOXA-AS2 knockdown effectively suppressed proliferation by blocking the cell cycle transition and caused apoptosis of PC cells in vitro and in vivo. HOXA-AS2 directly interacted with enhancer of zeste homolog 2 (EZH2) and lysine specific demethylase 1 (LSD1),which promoted PC cell growth ability. lncRNA-HOXA-AS2/EZH2/LSD1 complex may function as an oncogene in PC cell proliferation, and also provides a potential therapy target for PC.the mechanism of HOXA-AS2 in promoting PC cell proliferation and survival is more complex than we imagine. |
| Pubmed ID | 29312501 |
| Year | 2017 |
| Title | The lncRNA-HOXA-AS2/EZH2/LSD1 oncogene complex promotes cell proliferation in pancreatic cancer. |
External Links
| Links for HOXA-AS2 | GenBank HGNC NONCODE |
| Links for pancreatic cancer | OMIM COSMIC |